HALOHalozyme Therapeutics Inc.
HALO
Halozyme Therapeutics Inc.4,939
Mkt Cap
$8.41BVolume
1,980.0052W High
$82.2252W Low
$47.50PE Ratio
25.51HALO Fundamentals
Price
$70.93Prev Close
$66.41Open
$70.1150D MA
$65.59Beta
0.73Avg. Volume
1.39MEPS (Annual)
$2.56P/B
38.28Rev/Employee
$3.3M$10,373.12
Compact View
Not available
Not available
Earnings Recap
• Reported GAAP EPS of $1.27 up 32.29% YoY • Reported revenue of $376.71M up 42.23% YoY • Halozyme's Board of Directors authorized a new capital return program to repurchase up to $1B of outstanding common stock by December 31, 2028, with at least $400M expected in 2026.
Bullish
Halozyme reported strong royalty and product sales growth, driven by ENHANZE partner products and XYOSTED, while strategically expanding its drug delivery technology portfolio through recent acquisitions.
Bearish
Halozyme faced increased operating expenses and a 70% decrease in collaborative agreement revenue, with potential material impairment risk for customer relationship intangibles if a partner returns a target.